NCT05701215View on ClinicalTrials.gov

Venetoclax After TKI to Target Persisting Stem Cells in CML

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Venetoclax

Venetoclax will be taken orally once daily (400 mg) for 12 months

Trial Locations (2)

52074

Uniklinik der RWTH Aachen, Aachen

07747

Universitätsklinikum Jena, Jena

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

Ludwig-Maximilians - University of Munich

OTHER

collaborator

AbbVie

INDUSTRY

lead

Thomas Ernst, PD Dr. med.

OTHER